Home/Filings/4/0001567619-21-002852
4//SEC Filing

Lackner Mark 4

Accession 0001567619-21-002852

CIK 0001676725other

Filed

Feb 9, 7:00 PM ET

Accepted

Feb 10, 6:53 PM ET

Size

20.6 KB

Accession

0001567619-21-002852

Insider Transaction Report

Form 4
Period: 2021-02-08
Lackner Mark
SVP, Head of Biology
Transactions
  • Exercise/Conversion

    Common Stock

    2021-02-08$6.98/sh+300$2,094300 total
  • Sale

    Common Stock

    2021-02-08$21.02/sh100$2,102200 total
  • Sale

    Common Stock

    2021-02-08$21.00/sh200$4,2000 total
  • Exercise/Conversion

    Common Stock

    2021-02-10$6.98/sh+596$4,160596 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2021-02-1059633,014 total
    Exercise: $6.98Exp: 2028-12-11Common Stock (596 underlying)
  • Sale

    Common Stock

    2021-02-09$21.05/sh1,104$23,2340 total
  • Sale

    Common Stock

    2021-02-10$21.00/sh596$12,5160 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2021-02-0830034,714 total
    Exercise: $6.98Exp: 2028-12-11Common Stock (300 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2021-02-091,10433,610 total
    Exercise: $6.98Exp: 2028-12-11Common Stock (1,104 underlying)
  • Exercise/Conversion

    Common Stock

    2021-02-09$6.98/sh+1,104$7,7061,104 total
Footnotes (3)
  • [F1]The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
  • [F2]This transaction was executed in multiple trades in prices ranging from $21.00 to $21.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F3]25% of the shares subject to the option vest on the first anniversary measured from December 11, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Documents

1 file

Issuer

IDEAYA Biosciences, Inc.

CIK 0001676725

Entity typeother

Related Parties

1
  • filerCIK 0001777413

Filing Metadata

Form type
4
Filed
Feb 9, 7:00 PM ET
Accepted
Feb 10, 6:53 PM ET
Size
20.6 KB